A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Crossref DOI link: https://doi.org/10.1038/s41598-022-23834-1
Published Online: 2022-11-15
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yin, Yanchao
Shu, Yamin
Zhu, Junru
Li, Feie
Li, Juan
Text and Data Mining valid from 2022-11-15
Version of Record valid from 2022-11-15
Article History
Received: 9 August 2022
Accepted: 7 November 2022
First Online: 15 November 2022
Competing interests
: The authors declare no competing interests.